Trimer-Tag (Human CICP, Type I Collagen) Binding Antibody, Mouse Monoclonal [MA501B-100 or MA501B-025] 

Endo180 has been shown to be a collagen receptor and functions in both collagen turnover (Reference 1, see below) and cell adhesion (2). The C-terminal region of collagen (C-prodomain, also known as CICP) was found to be involved in binding to Endo180 (1). The C-prodomain of human Type I alpha collagen (Trimer-Tag) which is capable of self- trimerization via interchain disulfide bonds has been invented by Dr. Peng Liang, the founder of GenHunter, for producing recombinant trimeric biologics and viral antigens in vaccine development (2, 3). S-Trimer is a SARS-CoV-2 COVID-19 vaccine candidate produced by Clover Biopharmaceuticals under an exclusive licensing agreement with GenHunter and has received close to $400 million dollars in support from CEPI in clinical development and commercialization (3). The resulting COVID vaccine (SCB-2019) received EUA approval in China in December 2022.

GenHunter has 1 mouse monoclonal antibody against human Trimer-Tag which is CICP from human Col I(alpha). In addition, we offer has 4 monoclonal antibodies against human Endo180 (a neutralizing mAb and 3 binding mAbs) plus a recombinant human Endo180-Fc fusion protein.

Trimer-Tag/Collagen/Endo180 Antibody & Antigen Products Available:

References:

1. Thomas, E.K. et al: Endo180 Binds to the C-terminal Region of Type I Collagen. (2005) Journal of Biological Chemistry. 280:22596-22605. https://www.jbc.org/article/S0021-9258(20)61425-9/fulltext
2. Liu, H. et al: Improvement of pharmacokinetic profile of TRAIL via Trimer-Tag enhances its antitumor activity in vivo. (2017) Scientific Reports. 7:8953. https://www.nature.com/articles/s41598-017-09518-1
3. Liang. J.G. et al: S-Trimer, a COVID-19 subunit vaccine candidate, induces protective immunity in nonhuman primates. (2021) Nature Communications. 12:1346. https://www.nature.com/articles/s41467-021-21634-1

All products are FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC PROCEDURES.